ISRG Intuitive Surgical
Wonderful moat, excellent stewards, but price already bakes in growth this decelerating giant likely can't deliver.
The business
Intuitive Surgical designs, manufactures, and sells the da Vinci robotic surgical system on a razor-and-blades model: it sells/leases capital equipment to hospitals, then earns high-margin recurring revenue from disposable instruments, accessories, and service contracts tied to procedure volume. Growth comes from placing more systems, driving utilization per system higher, and expanding into new procedure types (urology, gynecology, general surgery, now soft tissue).
Quality gate · 81/100
Moat & management
| Moat | wide moat |
| Source | switching costs |
| Trajectory | stable |
| Management | excellent |
Surgeon retraining costs, multi-year hospital capital commitments, a large installed base of trained surgeons/staff, and FDA approval hurdles create durable switching costs and entry barriers; two-plus decades of >70% global soft-tissue robotic share despite well-funded entrants (Medtronic Hugo, J&J Ottava, Stryker) confirm the moat's persistence, though new entrants may erode pricing power at the margin over the next decade.
Net-cash balance sheet, essentially no debt, minimal share dilution (0.5% CAGR), and reinvestment consistently earning >12% median ROIC show disciplined, owner-oriented capital allocation with no empire-building or value-destructive M&A.
Owner-earnings inputs
| Owner earnings (TTM) | 3.22B |
| Owner-earnings yield | 2.5% |
| Free-cash-flow yield | 2.5% |
| Growth used (normalized) | 11.0% |
| Market-implied growth (reverse DCF) | 24.7% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 11.3% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 3.43B | 11.0% | 3.08B |
| 2 | 3.78B | 10.4% | 3.05B |
| 3 | 4.16B | 9.9% | 3.01B |
| 4 | 4.54B | 9.3% | 2.96B |
| 5 | 4.94B | 8.7% | 2.89B |
| 6 | 5.34B | 8.1% | 2.81B |
| 7 | 5.75B | 7.6% | 2.71B |
| 8 | 6.15B | 7.0% | 2.61B |
| 9 | 6.54B | 6.4% | 2.49B |
| 10 | 6.93B | 5.9% | 2.37B |
| 11 | 7.29B | 5.3% | 2.24B |
| 12 | 7.64B | 4.7% | 2.11B |
| 13 | 7.95B | 4.1% | 1.97B |
| 14 | 8.24B | 3.6% | 1.84B |
| 15 | 8.48B | 3.0% | 1.70B |
Key risks
- Reimbursement or hospital capex pressure slowing system placements
- New credible competitors (Medtronic Hugo, J&J Ottava) eroding pricing/share over time
- Regulatory or safety incident impairing surgeon/hospital trust
- Deceleration as procedure penetration in core specialties matures
Catalysts
- Expansion into general/soft-tissue surgery categories still in early penetration
- International (China, Europe, Japan) system placement growth
- Newer platform (da Vinci 5) driving instrument/accessory upgrade cycle
Recent news
score · 8 articles
- Intuitive Surgical (ISRG) vs. Medtronic (MDT): Which MedTech Stock Looks Better Positioned for Growth?
- UBS reveals what’s next for Intuitive Surgical stock
- Is ISRG Winning the Next Phase of Robotic Surgery Beyond Urology?
- ALGN Stock Up Post Q2 Earnings and Revenue Beat, Margins Rise
- Intuitive Surgical (ISRG) Could Be 43% Undervalued On Bylaw Changes And Share Price Weakness
- This Stock Is Knocking on the Door of the Dividend Kings -- and Wall Street Thinks It Has Room to Run
- The Best House On The Block Costs The Most: ISRG
- GE HealthCare beats quarterly profit estimates on strong imaging demand, tariff refunds
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Net cash 3.3B credited to value (interest stripped from owner earnings to avoid double-counting). · Price pays for ~25%/yr owner-earnings growth over 15y (reverse DCF); model credits 11%. · Rich vs our conservative value, but a quality business is not a short — stance is WAIT for a better price, not sell.